Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status

PRINCETON, N.J., and PARIS, Nov. 23 Bristol-Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported todaythat they are terminating their license agreement for the development ofvinflunine, a chemotherapy agent under investigation for the treatment ofadvanced or metastatic bladder cancer and other tumor types. Vinflunine wasdeveloped by Pierre Fabre Medicament and licensed to Bristol-Myers Squibb in2004 for specific territories. Based on a review of the clinical developmentprogram and the decision not to file a new drug application for bladder cancerin the United States, coupled with an analysis of Bristol-Myers Squibb'sResearch & Development priorities, the companies have jointly decided that allrights licensed to Bristol-Myers Squibb for vinflunine will be returned toPierre Fabre Medicament.

"In Europe, Pierre Fabre Medicament intend to continue discussions withregulatory authorities and plan to file for the registration of vinflunine forbladder cancer in the first quarter of 2008," said P. Hurteloup, GeneralManager of Pierre Fabre Medicament Oncology Division. "We also areconsidering a range of further development options, including pursuing theproduct on a worldwide basis for the treatment of a number of cancers."

Bristol-Myers Squibb is a global pharmaceutical and related health careproducts company whose mission is to extend and enhance human life.

Pierre Fabre Medicament is a French private group dedicated to consumersand patients from health to beauty.

SOURCE Bristol-Myers Squibb Company; Pierre Fabre Medicament

Latest Press Release on General News

OrthAlign Expands Lantern® Hip Platform to Support Posterior-Based Surgical Approaches in Total Hip Arthroplasty

PR Newswire IRVINE, Calif., Dec. 16, 2025 New software broadens market reach and enables surgeons to use Lantern Hip with their preferred surgical approach, including posterior-based...

Manual Recline Provides Invacare America Wheelchair Users a Simple, Practical Option for Pressure Relief

PR Newswire ELYRIA, Ohio and CONCORD, ON, Dec. 9, 2025 Motion Concepts mechanism now accessible to all customers ELYRIA, Ohio and CONCORD, ON, Dec. 9, 2025 /PRNewswire/ -- Gently...

Advita Ortho Wins Innovation Award for Soft Tissue Balancing in Knee Replacement Surgery

PR Newswire GAINESVILLE, Fla., Dec. 16, 2025 GAINESVILLE, Fla., Dec. 16, 2025 /PRNewswire/ -- Advita Ortho, a global medical technology leader, has been awarded the Innovation award ...

New Modeling Approach Sheds Light on Rare Gut Disease

PR Newswire NEW YORK, Dec. 16, 2025 NEW YORK, Dec. 16, 2025 /PRNewswire/ -- During development of the digestive system, a complex network of nerves forms around it, creating a "secon...

ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy

PR Newswire SEOUL, South Korea, Dec. 15, 2025 SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodeg...

MEDINDIA

Search Medindia

Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status

Latest Press Release on General News